Replies to post #182647 on Biotech Values

[jbog]

The drop from $11.50 to $10. is trivial. The drop from $20 to $10 is what needs to be evaluated.

[DewDiligence]

MNTA—I'm guessing part the sharp drop today (in addition to increased burn) was perhaps investors expected some sort of assurance or update on copax apprvoal which leads me to believe the drop will be short lived…

Unless the investors were newbies, it’s hard to see how they could have expected MNTA to disseminate material Copaxone information at a pre-scheduled event. Thus, I think the worry about increased cash burn (and the large sell-off in the broad market) fully explains the share-price move yesterday.

If MNTA were already taking in money from Copaxone, the cash usage for the newly disclosed programs wouldn’t have been an issue, IMO.